2017. ISPOR Annual International Meeting – Non-progression on treatment with avelumab contributed to gains in health utility scores with metastatic Merkel Cell Carcinoma

Kaufman H, Hunger M, Mahnke L, Schlichting M, Bharmal M. Non-progression on treatment with avelumab contributed to gains in health utility scores with metastatic Merkel Cell Carcinoma. Value Health. 2017 May;20(5):A119-A120. Presented at: ISPOR 22nd Annual International Meeting; May 22, 2017; Boston, MA, USA.